Glenmark

- Read more about Glenmark Pharmaceuticals Entered Into Agreement With Poland Based Celon for Generic Seretide Accuhaler
Glenmark Pharmaceuticals has entered into an agreement with Poland based Celon Pharma to develop and market a generic version of GlaxoSmithKline's Seretide Accuhaler in Europe used for treatment of lung diseases. The fluticasone/salmeterol dry powder inhaler is a combination product for the treatment of chronic obstructive pulmonary disease.
- Read more about Glenmark Pharma receives US FDA approval for voriconazole tablets
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval from the United States Food & Drug Administration (FDA) for voriconazole tablets, 50 mg and 200 mg of PF Prism C.V. (Prism).
- Read more about Glenmark’s GBR 830 entered into phase 2 studies in AD and celiac disease in US & Europe
Glenmark Pharmaceuticals S.A., GBR 830, a novel monoclonal antibody has completed clinical phase 1 dosing. GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation and survival. Glenmark has now completed clinical phase I studies for GBR 830 in the Netherlands.

(adsbygoogle = window.adsbygoogle || []).push({});
- Read more about Glenmark introduce third generation oral anti diabetic agent Teneligliptin priced at Rs. 19.90 per tab
In India Glenmark Pharmaceuticals has now introduced its new third generation oral anti diabetic agent Teneligliptin for type-2 diabetes at an affordable price of Rs. 19.90 per tablet. The first pan India launch of Teneligliptin under two brands: Ziten and Zita Plus took place in Bengaluru. The molecule gliptin comes under the category of DPP-4 inhibitors, which is backed by scientific data as being safe, well tolerated, weight neutral with low risk of hypoglycemia.

(adsbygoogle = window.adsbygoogle || []).push({});
- Read more about Glenmark Cholesterol-Lowering Drug Ezetimibe receive US Regulator's Nod
Glenmark Pharmaceuticals, has received approval from the US Food and Drug Administration (US FDA) for its cholesterol-lowering drug Ezetimibe. Ezetimibe is the generic version of Merck-Schering Plough's cholesterol-lowering drug with the product name Zetia.
- Read more about Glenmark receive US FDA approval for generic Dovonex cream, 0.005%
Glenmark Pharmaceuticals Inc., USA (Glenmark) get final approval by the United States Food & Drug Administration (FDA) for calcipotriene cream, 0.005 per cent, the therapeutic equivalent of Dovonex cream, 0.005 per cent of Leo Pharma A/S. Glenmark strategy to start to shipping of calcipotriene cream, 0.005 per cent immediately.
- Read more about Glenmark receive USFDA approval to sell Rufinamide
Glenmark Pharmaceuticals granted tentative approval by the US health regulator to sell Rufinamide, which is used to treat seizures caused by Lennox-Gastaut syndrome.
- Read more about Glenmark Pharma gets tentative ANDA approval from US FDA for rufinamide tablets USP
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received US FDA tentative ANDA approval for its rufinamide tablets USP, 200 mg and 400 mg.
- Read more about Glenmark receives US FDA approval for norethindrone acetate and ethinyl estradiol tablets USP
Glenmark Generics Inc. USA, a subsidiary of Glenmark Generics, has received the final approval from the United States Food and Drug Administration (USFDA) for sale of drugs meant to prevent post-menopause osteoporosis.USFDA granted Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/2.5 mcg and 1 mg/5 mcg.
13 April 2012

Opening in Glenmark Pharmaceuticals as Manager - Business Planning

Glenmark Pharmaceuticals today announced the settlement of litigation with Daiichi Sankyo and Genzyme Corporation regarding Glenmark's Abbreviated New Drug Application (ANDA) tiled with the US Food and Drug Administration (FDA) for Colesevelam Hydrochloride, a drug used in treatment of type-2 diabetes.